Back to top

RBC Capital Sticks to Their Hold Rating for Apogee Therapeutics (APGE)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Apogee Therapeutics on August 10 and set a price target of $135.00. The company’s sh...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Apogee Therapeutics Inc. (APGE)